Product Description
Mechanisms of Action: NMDA Antagonist,Potassium Channel Activator,GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Egypt | Germany | India | Indonesia | Ireland | Italy | Jordan | Malaysia | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Sri Lanka | Sweden | Taiwan | Tunisia | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|